IMpower133: Finally Moving the Needle in SCLC
By Stephen V. Liu, MD
Posted: March 1, 2019
The addition of atezolizumab to standard chemotherapy for extensive-stage SCLC achieved what, for decades, had been beyond...
Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for NSCLC
Posted: March 1, 2019
In the following interview, Jamie E. Chaft, MD, a medical oncologist at the Memorial Sloan Kettering Cancer Center, discusses new data...
Ongoing Clinical Challenges: Defining Immunotherapy Benefit for Patients With NSCLC and Poor Performance Status
This article is the first in a two-part series on ongoing challenges using immunotherapy in special populations. The second part of this series focuses on elderly...
Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou
Posted: December 2018
In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical...
Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to...
By Ross Soo, MB BS, PhD, FRACP
Posted: December 2018
The treatment of patients with advanced NSCLC harbouring an actionable oncogene with tyrosine kinase inhibitors (TKIs)...
Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC
By Mariano Provencio-Pulla, MD, PhD
Posted: December 2018
Patients with stage IIIA NSCLC with clinically evident N2 nodal spread have an overall 5-year survival rate of...
KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease
By Kara Nyberg, PhD
Posted: August 2018
The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint...
Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care
By Kara Nyberg, PhD
Posted: August 2018
Treatment advances for metastatic squamous cell carcinoma have long lagged behind those for other NSCLC subtypes, forcing patients with...
AACR 2018: First-Line Management of Advanced NSCLC Enters New Era
By Corey Langer, MD, IASLC Lung Cancer News Editor
Posted: June 2018
The therapeutic landscape irrevocably altered on April 17, 2018, when three pivotal trials—KEYNOTE 189,...
PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays
By Fred R. Hirsch, MD, PhD
Posted: April 2018
Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of...
